KRYSTAL BIOTECH INC.

Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

20 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung

13 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa

08 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference

01 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®

04 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)

19 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa

27 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at the Stifel 2023 Healthcare Conference

09 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update

06 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023

30 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference

28 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency

21 Sep 2023 09:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

07 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces Sale of Priority Review Voucher for $100 Million

21 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces Second Quarter 2023 Financial Results and Operational Highlights

07 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces Pipeline Expansion into Oncology and FDA Acceptance of IND Application for Lead Oncology Candidate KB707

26 Jul 2023 16:14:18 By Nasdaq GlobeNewswire

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of KB407 for the Treatment of Cystic Fibrosis

03 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at Upcoming Investor Conferences

05 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces $160 Million Private Placement Equity Financing

22 May 2023 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa

19 May 2023 13:57:02 By Nasdaq GlobeNewswire